The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy. Daver N, Vyas P, Huls G, Dohner H, et al. Blood 2025;146:601-611.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Daver N, Vyas P, Huls G, Dohner H, et al. The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy. Blood 2025;146:601-611.
PMID: 40233321